Ritu Salani, MD, details the health-related quality of life benefits associated with dostarlimab in the treatment of advanced endometrial cancer, which includes improvements in back and pelvic pain.
Videos
Ritu Salani, MD, describes the concordance between blinded independent central review and provider-assessed outcomes with dostarlimab among patients with advanced recurrent endometrial cancer in the phase 3 RUBY trial.
An overview of myeloproliferative neoplasms (MPNs) followed by an exploration of available treatment options and addressing differences in approach based on MPN subtypes such as essential thrombocytopenia, polycythemia vera, and myelofibrosis.
Insights concerning unmet needs in MDS treatment, ongoing trials, and recent updates in the treatment landscape.
Experts explain the strategies for optimal selection between different BCMA-targeting and non-BCMA-targeting bispecifics for the treatment of relapsed/refractory multiple myeloma.
Experts review recent data on non-BCMA-targeting bispecifics for the treatment of R/R MM.
Tanios S. Bekaii-Saab, MD, provides a look at an upcoming Cancer Network Around the Practice program in which a panel of experts will present the case of a patient with colorectal cancer, review updates from clinical trials, and provide insights on the role of ctDNA in treatment decision-making.
The panel discusses how non-BCMA-targeting bispecifics might be selected and sequenced in MM.
Cindy Varga, MD, details her experience with sequencing BCMA-targeting agents for patients with relapsed/refractory multiple myeloma.
Key opinion leaders in multiple myeloma management address barriers inherent in the selection and use of bispecifics.
Focused discussion on the mSMART guidelines for monitoring and managing adverse events associated with bispecific therapies in patients being treated for relapsed/refractory multiple myeloma.
Experts Scott A. Soefje, PharmD, and Kirollos S. Hanna, PharmD, share their perspectives on initial steps in initiating bispecific therapy for patients with multiple myeloma.
A panel of key opinion leaders from Mayo Clinic reflect on optimizing use of bispecifics in relapsed/refractory multiple myeloma, reviewing step-up dosing, administration, and followup strategies.
Experts comment on the subset analysis of the MAIA study in the frail NDMM patient population.
Noffar Bar, MD, discusses the MAIA study investigating a daratumumab combination therapy in patients with transplant-ineligible multiple myeloma.
Dr. Daver reviews treatment goals and treatment options for patients with higher-risk MDS.
Naval G. Daver, MD introduces myelodysplastic syndrome (MDS), focusing on the typical disease course, role of biomarker testing and risk stratification.
Gregory W. Roloff, MD, indicates that brexucabtagene autoleucel did not yield significant positive findings in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who were MRD positive.
Alicia K. Morgans, MD, MPH, from Dana-Farber Cancer Institute indicates that patients with non-metastatic castration-resistant prostate cancer are able to stay on treatment for long periods of time with darolutamide vs enzalutamide and apalutamide.
Key opinion leaders share comprehensive insight to the treatment armamentarium for patients with relapsed/refractory multiple myeloma.
Focused discussion on factors that aid in determining transplant ineligibility when a patient presents with newly diagnosed multiple myeloma.
The expert panel provides clinical insights on the key features of high-risk multiple myeloma and a look toward the clinical trial landscape.
An overview of multiple myeloma treatment options in the frontline and relapsed settings.
Experts Thomas Martin, MD; Ajay Nooka, MD; and Jeremy Larsen, MD, provide a broad overview of cytokine release syndrome as it relates to the management of multiple myeloma.
Key opinion leaders in multiple myeloma management reflect on the current role of stem cell transplant in patients with newly diagnosed disease.
Experts on multiple myeloma discuss approaches to laboratory workup and patient monitoring at the time of relapse.
Clinical experts examine the role of transplant in multiple myeloma and discuss key clinical trials and the impact of adding daratumumab to triplet therapy.
The education of patients on identifying and reporting adverse effects is a critical part of effective toxicity management.
A summary of updates from the MAIA and SWOG S0777 studies, with a focus on efficacy and tolerability data.
Thoughtful discussion centered around recently presented updates to the MASTER trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
How to Mitigate the Emotional, Logistical, and Financial Burdens of Cancer Treatment?
2
PEG Hydrogel Reduces Rectal Radiation During Cervical Cancer Therapy
3
As Late-Career Oncologists Retire, Who Will Fill the Geographic Gaps?
4
Examining Developments in Safe Administration of Nuclear Agents
5
